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Abstract: Thymomas are the most frequently encountered tumors of
the mediastinum and often present with either localized or locally
advanced disease. The prognosis in thymoma has been consistently
shown to correspond to the invasiveness of the tumor (as represented
by the Masaoka stage of the tumor) and the completeness of surgical
resection. Because treatment with a variety of different chemother-
apy regimens has demonstrated radiographic response rates greater
than 50% in patients with advanced thymoma, a number of inves-
tigators have explored the use of preoperative (induction, neoadju-
vant) therapy for patients with locally advanced thymoma. In this
review, we summarize the published experience with preoperative
therapy for thymoma and discuss ongoing clinical trials exploring
multimodality therapy for treatment of locally advanced thymoma.
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Although rare in the general population, thymomas are themost frequently encountered tumors of the mediastinum
and often present with either localized or locally advanced
disease. The prognosis in thymoma has been consistently
shown to correspond to the invasiveness of the tumor (as
represented by its Masaoka stage) and the completeness of
surgical resection.1–3 Approximately 50% of patients with
thymoma have a completely encapsulated tumor without
evidence of invasion. Stage I and II thymomas are generally
managed with surgery, and complete resection for such small
tumors can be generally anticipated. Patients with completely
resected stage I and II thymomas have 10-year survivals
estimated at more than 80%. However, some patients with
thymoma present with more advanced disease with local
invasion or spread to the pleura. Because thymomas are
located in the mediastinum, local invasion of the mediasti-
num and great vessels can present a daunting challenge
complete resection. Given the clear prognostic benefit of
complete surgical resection in such patients, a number of
investigators have explored the role of preoperative therapy
for optimal management of locally advanced thymoma.
SURGICAL RESECTION OF LOCALLY
ADVANCED THYMOMA
Achieving a complete resection remains the key to
treatment of thymoma, but for patients with locally advanced
disease and with disease involving the pleura (stage IVa),
complete resections can require extensive surgical resections.
Given the large areas encompassed by these tumors, optimal
exposure often requires more than the standard sternotomy,
and a hemiclamshell or even clamshell approach may provide
the best access. Thymoma patients are typically younger and
more fit than patients with lung or esophageal cancer and can
often tolerate such extended resections. One series reported
12 resections of thymomas invading the superior vena cava
without any significant morbidity or mortality and confirmed
that complete resection remained the most significant prog-
nostic factor.4 Stage IVA thymomas offer a particularly
difficult challenge. Despite the presence of disease metastatic
to the pleura, these lesions are still often amenable to resec-
tion. However, whether surgical resection of metastatic dis-
ease improves overall outcome has not been prospectively
established. In cases of extensive pleural disease, several insti-
tutions including our own have now reported small series of
extrapleural pneumonectomy for stage IVA disease with excel-
lent outcomes and low morbidity.5–7 Nonetheless, achieving a
complete resection in these cases remains challenging and re-
section rates in these series ranged from 60 to 67%.
CHEMOTHERAPY IN THYMOMA
Since treatment with a variety of different chemother-
apy regimens has demonstrated radiographic response rates
greater than 50%, a number of investigators have explored
the use of preoperative therapy for patients with locally
advanced thymoma. The two largest intergroup trials study-
ing chemotherapy in patients with advanced or metastatic
thymoma found response rates of 50% for regimens of
cisplatin, doxorubicin, and cyclophosphamide and 56% for
regimens of cisplatin and etoposide.8,9 Median survival times
in these trials ranged from 3 to 4 years and 5-year survivals
were estimated at 32 to 50%. Both regimens were well
tolerated. Toxicities were mild and primarily hematologic,
with roughly half of the patients having grade III or IV
leukopenia with either regimen. Cyclophosphamide and PE
remain the most frequently used chemotherapy regimens in
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advanced thymoma. More recently, investigators from the
Eastern Cooperative Oncology Group have reported their
evaluation of paclitaxel and carboplatin.10 In this trial of 24
patients with thymoma, the response rate was 33%, suggest-
ing that this newer regimen may not offer greater benefit for
patients with thymoma.
PREOPERATIVE CHEMOTHERAPY IN
THYMOMA
There is evidence that a multimodality approach incor-
porating chemotherapy or chemoradiotherapy before surgery
may improve resectability and outcomes in locally advanced
thymoma (Table 1). These scattered reports are a mixture of
disparate, sometimes outdated regimens with small numbers,
and some with some series dating back over two decades.
However, at least four groups have reported prospective
clinical trials exploring multimodality therapy for locally
advanced thymoma.11–14 Berruti et al. conducted a prospec-
tive clinical trial of cisplatin, doxorubicin, vincristine, and
cyclophosphamide in patients with stage III and IVa thy-
moma. They observed that five of six patients had a partial
response and then went on to surgery. Despite this high
response rate, only one patient achieved a complete surgi-
cal resection, the goal of induction therapy. The largest
prospective clinical trial reported in this setting was con-
ducted between 1990 and 2000 at the M.D. Anderson Cancer
Center, where patients with locally advanced thymoma re-
ceived induction cisplatin, doxorubicin, cyclophosphamide,
and prednisone, followed by surgery, radiation, and consoli-
dation chemotherapy. In that study, 17 of 22 patients had a
radiographic response after chemotherapy and six of 16
patients were found to have greater than 80% tumor necrosis
at the time of surgical resection. Finally, most recently,
Kunitoh et al.14 reported the results of the Japan Clinical
Oncology Group evaluation of weekly, dose dense chemo-
therapy followed by surgery for patients with locally ad-
vanced thymoma. In this study, the investigators observed a
62% response rate and 14% complete pathologic response
rate. These trials emphasize that prospective phase 2 trials
for patients with locally advanced thymoma are feasible.
IMPROVING ON INDUCTION THERAPY FOR
THYMOMA BY ADDITION OF RADIOTHERAPY
TO CHEMOTHERAPY
Radiation therapy is used to treat thymoma in patients
who cannot undergo complete surgical resection and is a
common component of postoperative therapy for patients
with locally advanced disease. In a variety of diseases,
combining radiation therapy with chemotherapy has been
demonstrated to improve response rates and increase the rate
of cure for potentially unresectable disease (e.g., stage III
non-small cell lung cancer, rectal cancer). This approach,
retrospectively reviewed by Wright et al.,15 has been associ-
ated with a 40% rate of more than 90% tumor necrosis after
combined cisplatin, etoposide, and radiation therapy for pa-
tients with locally advanced thymoma. To prospectively ex-
plore the value of incorporating radiation therapy into con-
ventional chemotherapy treatment plan for locally advanced
thymoma, Korst and colleagues are conducting a phase 2 trial
of cisplatin, etoposide, and concurrent radiotherapy for pa-
tients with locally advanced thymoma (NCT00387868). This
trial rigorously defines tumor characteristics that make pa-
tients eligible for enrollment, including tumor more than 8
cm in size, those between 5 and 8 cm with multifocal
calcification, heterogeneous appearance, irregular borders
or great vessel invasion or encirclement, or tumors less
than 5 cm with great vessel invasion or encirclement. The
primary endpoint of this clinical trial is complete patho-
logic response. After surgical resection, based on the
findings at the time of surgery, patients are treated with
observation, additional chemotherapy, or additional con-
current chemoradiotherapy (Figure 1).
TABLE 1. Induction Therapy for Thymoma
Author
No. of
Patients Chemotherapy
Response
(CR  PR)
Complete
Resection
Pathologic Complete
Response
Bretti et al.20 25 Etoposide, cisplatin or doxorubicin,
cisplatin, vincristine, cyclophosphamide
18/25 11/25 2/25
Lucchi et al.21 25 Cisplatin, epirubicin, etoposide 20
Venuta et al.22 15 Cisplatin, epirubicin, etoposide 10/15 1/15
Berruti et al.11 6 Doxorubicin, cisplatin, vincristine,
cyclophosphamide
5/6 1/6 0
Jacot et al.23 5 Cisplatin, doxorubicin, cyclophosphamide 4/5 1/5
Macchiarini et al.13 7 Cisplatin, epirubicin, etoposide 7/7 4/7
Kim et al.12 22 Cisplatin, doxorubicin, cyclophosphamide,
prednisone
17/22 16/21 6/16a
Rea et al.24 16 Doxorubicin, cisplatin, vincristine,
cyclophosphamide
16/16 11 5/16
Wright et al.15 10 Etoposide, cisplatin, radiation therapy 4/10 8/10 4/10b
Kunitoh et al.14 21 Cisplatin, vincristine, doxorubicin, etoposide 13/21 9/21 3/21
a 80% necrosis.
b 90% necrosis.
CR, complete response; PR, partial response.
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IMPROVING ON INDUCTION THERAPY FOR
THYMOMA BY ADDITION OF TARGETED
THERAPIES
In many advanced malignancies, significant improve-
ments in response rate and overall survival have been ob-
served after the addition of biologic therapies suggesting that
by incorporating this approach, we may improve outcomes
for patients with thymoma.
Staining for epidermal growth factor receptor (EGFR)
by immunohistochemistry is observed in a high percentage of
thymomas across all histologic types and stages of disease.16
However, activating EGFR mutations are rare with only two
exon 21 mutations found in 29 thymic tumors analyzed.17
Cetuximab is a monoclonal antibody directed against EGFR
that has demonstrated activity in patients with colorectal
cancer, squamous cell cancer of the head and neck, and
non-small cell lung cancer. Moreover, two separate reports
documenting clinical responses to cetuximab in patients with
advanced thymoma support the concept that EGFR inhibition
is a promising therapeutic avenue.18,19 Partial responses were
observed in three patients who had metastatic disease and had
progressive disease after at least two lines of prior therapy. In
two patients, a reduction in fluorodeoxyglucose uptake by
positron emission tomography was noted as well. Taken
together, these data suggest that incorporation of cetuximab
with chemotherapy in patients with locally advanced thy-
moma may improve the radiographic and pathologic response
rates and rate of complete resections.
To explore the incorporation of cetuximab into a pre-
operative chemotherapy regimen, there is an ongoing phase II
clinical trial of cetuximab with cisplatin, doxorubicin, and
cyclophosphamide in patients with locally advanced thy-
moma (Figure 2) (NCT01025089). This clinical trial aims to
enroll a total of 28 patients and uses the primary endpoint of
pathologic complete response rate. Of note, only patients with
thymoma are included and all patients with thymic carcinoma
are excluded from this clinical trial. To prospectively evalu-
ate the role of cetuximab alone in these patients with locally
advanced thymoma, patients receive an initial 4 weeks of
cetuximab before beginning chemotherapy combined with
cetuximab. Computed tomography scans will assess response
to cetuximab by itself as well as to cetuximab in combination
with chemotherapy. All patients will undergo surgical resec-
tion with a goal of complete resection. Additional exploratory
endpoints include evaluating the role of positron emission
tomography scan for identification of sites of disease and
predicting response to therapy and outcomes, pathologic
predictors of response to chemotherapy and cetuximab.
Given the importance of complete resection in the
optimal management of thymoma, ongoing studies hope to
define the most active combinations of therapy for further
validation in clinical trials. Prospective clinical trials are the
model for how we should proceed for evaluating therapy for
locally advanced thymomas. The described ongoing clinical
trials will teach us about the value of incorporating radiation
therapy or EGFR-targeted therapy into preoperative therapy
for thymoma. Results of ongoing prospective clinical trials
for patients with advanced thymoma will also lead to new
hypotheses for therapeutic approaches in treatment of locally
advanced thymoma. Induction therapy studies provide a
unique opportunity for evaluating tissue biomarkers to better
understand tumor biology and predict response to the thera-
pies that are currently being evaluated.
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